HONG KONG, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced continued ...

HONG KONG, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider, today announced continued ...

Nano Labs Ltd (NASDAQ: NA) is reshaping its capital strategy as it leans further into digital assets and shareholder returns amid a volatile year for the stock. The stock gained on Wednesday after it ...

A positively-charged dextran nano-photosensitizer (p-Dex PS) facilitates TAM-mediated delivery and sublethal light-induced metabolic reprogramming, which boost the TAM polarization and subsequently ...

HONG KONG, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced the launch of its ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Nano Labs Ltd. Sponsored ...

Humanity pretty much has Pi figured out at this point. We’ve calculated it many times over and are confident about what it is down to many, many decimal places. However, if you fancy estimating it ...

New York, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on ...

New York, New York--(Newsfile Corp. - July 14, 2025) - NANO Nuclear Energy Inc. (NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing ...

Hi, I'm Bill. I'm a software developer with a passion for making and electronics. I do a lot of things and here is where I document my learning in order to be able to inspire other people to make ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In ...